American Journal of Epidemiology Advance Access originally published online on December 21, 2005
American Journal of Epidemiology 2006 163(3):262-270; doi:10.1093/aje/kwj047
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Contribution |
Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform Effect
1 Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
2 Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
3 Department of Epidemiology, Harvard School of Public Health, Boston, MA
4 i3 Drug Safety, Auburndale, MA
5 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
6 Department of Biostatistics, Harvard School of Public Health, Boston, MA
7 Massachusetts Veterans Epidemiology Research and Information Center, Boston VA Healthcare System, Boston, MA
8 Institute of Epidemiology and Social Medicine, University of Muenster, Muenster, Germany
Correspondence to Dr. Tobias Kurth, Division of Aging, Brigham and Women's Hospital, 1620 Tremont Street, Boston, MA 02120 (e-mail: tkurth{at}rics.bwh.harvard.edu).
Observational studies often provide the only available information about treatment effects. Control of confounding, however, remains challenging. The authors compared five methods for evaluating the effect of tissue plasminogen activator on death among 6,269 ischemic stroke patients registered in a German stroke registry: multivariable logistic regression, propensity score–matched analysis, regression adjustment with the propensity score, and two propensity score–based weighted methods—one estimating the treatment effect in the entire study population (inverse-probability-of-treatment weights), another in the treated population (standardized-mortality-ratio weights). Between 2000 and 2001, 212 patients received tissue plasminogen activator. The crude odds ratio between tissue plasminogen activator and death was 3.35 (95% confidence interval: 2.28, 4.91). The adjusted odds ratio depended strongly on the adjustment method, ranging from 1.11 (95% confidence interval: 0.67, 1.84) for the standardized-mortality-ratio weighted to 10.77 (95% confidence interval: 2.47, 47.04) for the inverse-probability-of-treatment-weighted analysis. For treated patients with a low propensity score, risks of dying were high. Exclusion of patients with a propensity score of <5% yielded comparable odds ratios of approximately 1 for all methods. High levels of nonuniform treatment effect render summary estimates very sensitive to the weighting system explicit or implicit in an adjustment technique. Researchers need to be clear about the population for which an overall treatment estimate is most suitable.
causality; cerebrovascular accident; confounding factors (epidemiology); data interpretation, statistical; logistic models; models, statistical; observational study
Abbreviations: CI, confidence interval; IPTW, inverse-probability-of-treatment weighted; SMR, standardized mortality ratio; t-PA, tissue plasminogen activator
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. I. Brixner, X. Ye, T.-C. Chu, W. A. Blumentals, and T. I. Hassanein Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin Am. J. Health Syst. Pharm., December 15, 2009; 66(24): 2171 - 2178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Zilberberg, B. H. Nathanson, S. Sadigov, T. L. Higgins, M. H. Kollef, and A. F. Shorr Epidemiology and Outcomes of Clostridium difficile-Associated Disease Among Patients on Prolonged Acute Mechanical Ventilation Chest, September 1, 2009; 136(3): 752 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, J. M. Donohue, J. R. Lave, G. O'Donnell, and J. P. Newhouse The Effect of Medicare Part D on Drug and Medical Spending N. Engl. J. Med., July 2, 2009; 361(1): 52 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. H. Groenwold, A. W. Hoes, and E. Hak Impact of influenza vaccination on mortality risk among the elderly Eur. Respir. J., July 1, 2009; 34(1): 56 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurth and C. Tzourio Treating Patients With Ischemic Stroke With Tissue Plasminogen Activator in the 3.5- to 4-Hour Window: Numbers Support Benefit but the Message Is to Still Go Fast Stroke, July 1, 2009; 40(7): 2295 - 2296. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lunt, D. Solomon, K. Rothman, R. Glynn, K. Hyrich, D. P. M. Symmons, T. Sturmer, and the British Society for Rheumatology Biologics Reg Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification Am. J. Epidemiol., April 1, 2009; 169(7): 909 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A Blumentals, S. T Harris, R. E Cole, L. Huang, and S. L Silverman Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Alendronate and Risedronate Ann. Pharmacother., April 1, 2009; 43(4): 577 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Ravaud, R-M Flipo, I Boutron, C Roy, A Mahmoudi, B Giraudeau, and T Pham ARTIST (osteoarthritis intervention standardized) study of standardised consultation versus usual care for patients with osteoarthritis of the knee in primary care in France: pragmatic randomised controlled trial BMJ, February 23, 2009; 338(feb23_1): b421 - b421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurth, C. Tzourio, and M.-G. Bousser Migraine: A Matter of the Heart? Circulation, September 30, 2008; 118(14): 1405 - 1407. [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Hansen The prognostic analogue of the propensity score Biometrika, June 1, 2008; 95(2): 481 - 488. [Abstract] [PDF]
|
|
|
|
|
|
C. Schmoor, A. Caputo, and M. Schumacher Evidence from Nonrandomized Studies: A Case Study on the Estimation of Causal Effects Am. J. Epidemiol., May 1, 2008; 167(9): 1120 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Bos, P. J. Koudstaal, A. Hofman, and M. M.B. Breteler Decreased Glomerular Filtration Rate Is a Risk Factor for Hemorrhagic But Not for Ischemic Stroke: The Rotterdam Study Stroke, December 1, 2007; 38(12): 3127 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mansson, M. M. Joffe, W. Sun, and S. Hennessy On the Estimation and Use of Propensity Scores in Case-Control and Case-Cohort Studies Am. J. Epidemiol., August 1, 2007; 166(3): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurth, P. U. Heuschmann, A. M. Walker, K. Berger, M. L. Flaherty, B. Kissela, P. Khatri, R. M. Dubinsky, and S. M. Lai Mortality of stroke patients treated with thrombolysis: Analysis of nationwide inpatient sample Neurology, February 27, 2007; 68(9): 710 - 711. [Full Text] [PDF]
|
|